Coming October 29: SITC releases its late-breaking abstract titles. We’ll add their presenting authors’ institutions to this guide once they’re out.

Accession Therapeutics at SITC 2026

Nov 4–8, 2026 Phoenix, AZ ~6k attendees Website

Accession Therapeutics brings 3 presentations to SITC 2026 in Phoenix. Its program centres on tumor-targeting viruses given into a vein that make their drug payload inside the tumor. One concrete example, ATTR-02, has tumors produce a universal T-cell engager to tackle tumors whose cells differ from one another.

Organization	SITC 2026 Attendance
AT Accession Therapeutics Oxford, United Kingdom
Biotech A biotechnology company developing targeted oncolytic virus therapies for cancer.	Talk Fri Nov 6 1:00pm–1:08pm Part of Session 105a: Rapid Oral - Basic 1 Precision Immunovirotherapy via TROCEPT enables αvβ6-directed tumor targeting and local immune checkpoint inhibitor delivery after IV administration. 301A Vaccines · New agents Poster Sat Nov 7 12:30–1:30pm 6:40–8:10pm A phase 1 study of ATTR-01, an I.V. delivered novel oncolytic adenovirus expressing an anti-PD-L1 antibody, in participants with selected epithelial cancers expressing αvβ6 integrin. Exhibition Halls 4-6 · Poster 550 Vaccines · Clinical Poster Sat Nov 7 12:30–1:30pm 6:40–8:10pm Pharmaceutical Surgery by Design: IV dosed virus ATTR‑02 enables in-tumor production of a universal bispecific T cell engager to address tumor heterogeneity Exhibition Halls 4-6 · Poster 1054 New agents

Organization

SITC 2026 Attendance

Accession Therapeutics

Oxford, United Kingdom

Biotech

A biotechnology company developing targeted oncolytic virus therapies for cancer.

Talk

Fri Nov 6
1:00pm–1:08pm

Part of Session 105a: Rapid Oral - Basic 1

Precision Immunovirotherapy via TROCEPT enables αvβ6-directed tumor targeting and local immune checkpoint inhibitor delivery after IV administration.

301A

Vaccines · New agents